Arkolith/Insider Trading/RVNC/Form 4

Foley Mark J

President & CEO, DirectorRevance Therapeutics, Inc. (RVNC) · full profile →Form 4 · filed Feb 6, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
5 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 6, 2025Grant(A)85K—$085K
Feb 6, 2025Disposed to issuer(D)28K——0
Feb 6, 2025Disposed to issuer(D)85K——0
Feb 4, 2025Tender(U)997K$3.65$3.6M28K
Feb 4, 2025Tender(U)111K$3.65$405K0

Transaction Codes

A
Grant / award
D
Disposition to the issuer
U
See SEC Form 4 code table

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-015363) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML